Related Experiment Video
Updated: Dec 18, 2025

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Sleep-Disordered Breathing in Children with Prader-Willi Syndrome in Relation to Growth Hormone Therapy Onset
Maja Zimmermann1, Constanze Laemmer2, Joachim Woelfle3
1Pediatric Endocrinology and Diabetology, Children's Hospital, University of Bonn, Bonn, Germany.
Insights
Early growth hormone (GH) therapy is safe for Prader-Willi syndrome (PWS) children with sleep apnea. Sleep apnea development in PWS children is independent of GH treatment onset, but regular sleep monitoring is recommended.
Area of Science:
- Pediatric Endocrinology
- Sleep Medicine
- Genetics
Background:
- Prader-Willi syndrome (PWS) is a complex genetic disorder associated with various health issues, including sleep-related breathing disorders.
- Obstructive sleep apnea (OSA) is a common comorbidity in children with PWS, impacting their growth and development.
- The timing of growth hormone (GH) therapy initiation in relation to sleep apnea onset in PWS patients is not well-established.
Purpose of the Study:
- To investigate the relationship between the age of initiating growth hormone (GH) therapy and the presence and severity of sleep apnea in children with Prader-Willi syndrome (PWS).
- To assess the impact of early versus later GH therapy onset on key sleep apnea indices in PWS children.
Main Methods:
- A longitudinal study analyzing cardiorespiratory polygraphy data from 62 PWS children, categorized into two groups based on GH therapy onset (before or after one year of age).
- Sleep parameters including obstructive apnea hypopnea index (OAHI), central apnea index (CAI), oxygen desaturation index (ODI), and peripheral blood oxygen saturation (SpO2) were measured at baseline and at multiple time points post-GH therapy initiation.
- Statistical analysis was performed to compare sleep apnea outcomes between the two treatment groups.
Main Results:
- No significant differences in OAHI, CAI, ODI, or SpO2 were observed between PWS children who started GH therapy early versus later.
- While pathological obstructive sleep apnea (OSA) increased in the early treatment group within the first three months, it normalized below baseline after one year in both groups.
- The oxygen desaturation index (ODI) showed a significant decrease during GH therapy in both groups, indicating improvement in oxygenation.
Conclusions:
- Obstructive sleep apnea in Prader-Willi syndrome children appears to develop independently of the timing of growth hormone therapy initiation.
- Initiating GH therapy early in PWS children with sleep apnea is considered safe.
- Regular sleep monitoring is crucial for PWS children undergoing GH therapy, regardless of treatment onset age.
Objective:
The aim of this study was to consider sleep apnea in Prader-Willi syndrome (PWS) children depending on age at growth hormone (GH) therapy onset.
Study Design:
We analyzed longitudinally cardiorespiratory polygraphy of 62 PWS children (aged 0-2.5 years at baseline). Twenty-one children (Group A) started GH-therapy during and 41 children (Group B) after their first year of life. Data were acquired before, at 3 and 6 months, then 1.2, 2.2, and 3.2 years after GH onset. Outcomes were determined with the obstructive apnea hypopnea index (OAHI), central apnea index (CAI), oxygen desaturation index (ODI), and by measuring obstructive sleep apnea (OSA) and peripheral blood oxygen saturation (SpO2).
Results:
We observed no significant differences in OAHI, CAI, ODI, and SpO2 depending on treatment onset. At baseline, 5/21 patients (23.8%) in Group A versus 15/41 patients (36.6%) in Group B showed pathological sleep apnea (OAHI ≥1.5). Pathological OSA increased significantly in Group A during the first 3 months of therapy but dropped below baseline after 1 year in both groups. ODI changed during GH therapy in both groups (from 4.0 to 2.6 in Group A, and 3.6 to 1.6 in Group B; baseline to 3.2 years; p < 0.05).
Conclusions:
OSA in PWS children appears to develop independently of treatment onset. Treatment may therefore safely be initiated early but should be accompanied by regular sleep analysis.
More Related Videos
04:56Laryngeal Mask Airway LMA Placement in a Neonatal Patient Simulator Using a Non-Inflatable Supraglottic Airway SGA
Published on: July 14, 2023
04:53Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
Published on: October 18, 2024
Related Concept Videos
Sleep Apnea
The condition is more prevalent among...
Alterations in Respiration II
In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes...
Acute Respiratory Failure-IV
Respiratory Volumes and Capacities I
Other Pulmonary Disorders
REM Sleep Behavior Disorder
RBD is significantly associated with...